BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34434254)

  • 1. Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma.
    Alkhayyat M; Kumar P; Sanaka KO; Thota PN
    Therap Adv Gastroenterol; 2021; 14():17562848211033730. PubMed ID: 34434254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Chemoprevention in Barrett's Esophagus.
    Moayyedi P; El-Serag HB
    Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
    Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
    Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Thrift AP
    Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
    Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
    Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic surveillance in Barrett's esophagus.
    Lunedei V; Bazzoli F; Pozzato P; De Luca L; Zagari RM; Fossi S; Ricciardiello L; Maltoni S; Roda E
    Minerva Gastroenterol Dietol; 2002 Jun; 48(2):63-71. PubMed ID: 16489297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Barrett's esophagus and esophageal adenocarcinoma.
    Shaheen NJ
    Gastroenterology; 2005 May; 128(6):1554-66. PubMed ID: 15887151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
    Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
    J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Wang F; Lv ZS; Fu YK
    Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
    Heath EI; Canto MI; Wu TT; Piantadosi S; Hawk E; Unalp A; Gordon G; Forastiere AA;
    Dis Esophagus; 2003; 16(3):177-86. PubMed ID: 14641306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's esophagus.
    Falk GW
    Gastroenterology; 2002 May; 122(6):1569-91. PubMed ID: 12016424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
    Wong T; Tian J; Nagar AB
    Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical decision analysis of chemoprevention against esophageal adenocarcinoma.
    Sonnenberg A; Fennerty MB
    Gastroenterology; 2003 Jun; 124(7):1758-66. PubMed ID: 12806608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Acid Suppression in Barrett's Esophagus.
    Elias PS; Castell DO
    Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.